SLC5A1 and hepatocellular carcinoma: On the contrary, trilobatin, a novel SGLT-1/2 inhibitor, increased the HepG2 cell proliferation rate at a dose of 10, 50 and 100 μΜ, while incubation of human HCC cells with tofogliflozin at various concentrations did not alter the HCC cell proliferation rate [89].